PL3191120T3 - Zastosowanie antagonistów il-17 do hamowania postępu uszkodzeń strukturalnych u pacjentów z łuszczycowym zapaleniem stawów - Google Patents

Zastosowanie antagonistów il-17 do hamowania postępu uszkodzeń strukturalnych u pacjentów z łuszczycowym zapaleniem stawów

Info

Publication number
PL3191120T3
PL3191120T3 PL15767597.6T PL15767597T PL3191120T3 PL 3191120 T3 PL3191120 T3 PL 3191120T3 PL 15767597 T PL15767597 T PL 15767597T PL 3191120 T3 PL3191120 T3 PL 3191120T3
Authority
PL
Poland
Prior art keywords
antagonists
progression
inhibit
psoriatic arthritis
structural damage
Prior art date
Application number
PL15767597.6T
Other languages
English (en)
Polish (pl)
Inventor
Shephard Mpofu
Hanno Richards
Gregory LIGOZIO
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3191120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3191120T3 publication Critical patent/PL3191120T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
PL15767597.6T 2014-09-10 2015-09-08 Zastosowanie antagonistów il-17 do hamowania postępu uszkodzeń strukturalnych u pacjentów z łuszczycowym zapaleniem stawów PL3191120T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
PL3191120T3 true PL3191120T3 (pl) 2024-08-26

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15767597.6T PL3191120T3 (pl) 2014-09-10 2015-09-08 Zastosowanie antagonistów il-17 do hamowania postępu uszkodzeń strukturalnych u pacjentów z łuszczycowym zapaleniem stawów

Country Status (22)

Country Link
US (2) US11278618B2 (enExample)
EP (2) EP4406969A3 (enExample)
JP (4) JP2017528465A (enExample)
KR (2) KR20230170796A (enExample)
CN (4) CN113069542A (enExample)
AU (2) AU2015313827C1 (enExample)
BR (1) BR112017003332A2 (enExample)
CA (1) CA2960754A1 (enExample)
DK (1) DK3191120T3 (enExample)
ES (1) ES2981697T3 (enExample)
FI (1) FI3191120T3 (enExample)
HR (1) HRP20240921T1 (enExample)
HU (1) HUE067081T2 (enExample)
LT (1) LT3191120T (enExample)
MX (1) MX2017003216A (enExample)
PL (1) PL3191120T3 (enExample)
PT (1) PT3191120T (enExample)
RS (1) RS65851B1 (enExample)
RU (1) RU2697383C2 (enExample)
SI (1) SI3191120T1 (enExample)
SM (1) SMT202400285T1 (enExample)
WO (1) WO2016038538A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278618B2 (en) 2014-09-10 2022-03-22 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
MY207225A (en) 2015-10-27 2025-02-06 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
TW201842933A (zh) * 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
WO2019087133A1 (en) * 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
JP2022536088A (ja) * 2019-06-04 2022-08-12 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
KR102604172B1 (ko) 2019-12-05 2023-11-22 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 베체트병 또는 류마티스 관절염 예방 또는 치료용 약학조성물
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JP5237366B2 (ja) 2007-06-20 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 炎症性関節疾患に対する抗ｉｌ−１７ａ治療のための関節破壊のバイオマーカー
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
RU2665954C1 (ru) * 2010-10-08 2018-09-05 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
TWI616204B (zh) * 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
KR20140097178A (ko) * 2011-11-21 2014-08-06 노파르티스 아게 IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
US11278618B2 (en) * 2014-09-10 2022-03-22 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Also Published As

Publication number Publication date
RS65851B1 (sr) 2024-09-30
RU2697383C2 (ru) 2019-08-13
DK3191120T3 (da) 2024-07-15
JP2025024104A (ja) 2025-02-19
PT3191120T (pt) 2024-07-16
JP2023109973A (ja) 2023-08-08
AU2015313827C1 (en) 2018-08-30
ES2981697T3 (es) 2024-10-10
RU2017107501A3 (enExample) 2019-03-12
WO2016038538A1 (en) 2016-03-17
US11278618B2 (en) 2022-03-22
HRP20240921T1 (hr) 2024-10-11
JP2021152021A (ja) 2021-09-30
AU2015313827B2 (en) 2018-02-15
SI3191120T1 (sl) 2024-10-30
JP7288927B2 (ja) 2023-06-08
CA2960754A1 (en) 2016-03-17
HUE067081T2 (hu) 2024-09-28
EP4406969A3 (en) 2024-11-27
JP7591092B2 (ja) 2024-11-27
LT3191120T (lt) 2024-07-25
CN115957326A (zh) 2023-04-14
EP3191120B1 (en) 2024-04-10
BR112017003332A2 (pt) 2017-11-28
FI3191120T3 (fi) 2024-07-10
EP4406969A2 (en) 2024-07-31
AU2015313827A1 (en) 2017-02-16
CN115944734A (zh) 2023-04-11
CN113069542A (zh) 2021-07-06
KR20170045240A (ko) 2017-04-26
US20170281762A1 (en) 2017-10-05
AU2018201410A1 (en) 2018-03-22
RU2017107501A (ru) 2018-10-10
EP3191120A1 (en) 2017-07-19
CN107073110A (zh) 2017-08-18
KR20230170796A (ko) 2023-12-19
MX2017003216A (es) 2017-05-23
US20220313818A1 (en) 2022-10-06
SMT202400285T1 (it) 2024-09-16
JP2017528465A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
SI3221363T1 (sl) Protitelesa proti CD73 in njihova uporaba
SMT202400285T1 (it) Uso di antagonisti di il-17 per inibire la progressione del danno strutturale in pazienti affetti da artrite psoriasica
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
GB201416102D0 (en) Impovements In or Relating To Shower Rods
IL251904A0 (en) Apilimod for use in the treatment of melanoma
GB201702982D0 (en) Improvements in or relating to centralisers
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
GB201415153D0 (en) Improvements in or relating to showers
PT3137622T (pt) Métodos para reduzir o declínio da capacidade vital
GB201705271D0 (en) Technology to facilitate and promote the use of environmentally-friendly transport
ZA201702488B (en) Improvements in or relating to connecting devices
PL2965765T3 (pl) Zastosowanie adelmidrolu w leczeniu dysfunkcji nabłonka
GB201405013D0 (en) Improvements in or relating to manufacture of packaging
GB201416463D0 (en) Improvements in or relating to temporary structures
GB2545716B (en) Improvements in or relating to the separation of radon
GB201419593D0 (en) Improvements in or relating to connecting devices
UA28633S (uk) Кутова оздоба до пам'ятника намогильного
ZA201408464B (en) Composition for the use in treatment of asthma
GB201415704D0 (en) Improvements in or Relating to Storage
GB201415705D0 (en) Improvements in or Relating to Storage
GB201415702D0 (en) Improvements in or relating to storage
GB201404391D0 (en) Novel compositions having use in therapy
GB201406078D0 (en) Improvements in or relating to storage